Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease
Sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
A PHASE2 clinical study on Behcet Disease and Behcet Syndrome, this trial is completed. The trial is conducted by Ainos, Inc. (f/k/a Amarillo Biosciences Inc. and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- Nobel Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .